Literature DB >> 21723098

Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling.

P-M Llorca1, O Blanc, L Samalin, M Bosia, R Cavallaro.   

Abstract

PURPOSE: This study aimed at using latent variable modelling to explore the significantly contributing variables to functioning in schizophrenia patients.
METHODS: The study cohort comprised 296 schizophrenia patients evaluated once for demographic characteristics, functioning (FROGS, SWN-K, QLS) and symptomatology (Positive and Negative Syndrome Scale [PANSS]). First exploratory multivariate analyses were conducted and then a model with functioning as a latent variable was proposed and tested with the data.
RESULTS: Symptomatology as negative, cognitive and excitation factor are significant predictors of functioning assessed through FROGS (P<0.0001), SWN-K and QLS (P<0.001). The model was constructed with functioning defined as a latent variable, indicators are subscores on FROGS, SWN-K, QLS and exogenous variable included symptomatology, Duration of Untreated Psychosis (DUP) and educational level.
CONCLUSION: Using the five clinical dimensions of the PANSS, (Positive, Negative, Cognitive, Anxiety/Depression and Excitation) the negative and cognitive dimensions are highly correlated via the latent variable to the three dimensions of functioning evaluated by the FROGS: "daily life", "social functioning" and "treatment" and the QLS subscores (interpersonnal, common object, instrumental role). Educationnal level is positively linked to functioning but not DUP. The model emphasizes the need for treatment strategies that have an effect on cognitive-factors, to improve functioning in schizophrenia.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21723098     DOI: 10.1016/j.eurpsy.2011.01.010

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  7 in total

1.  The association of psychopathology with concurrent level of functioning and subjective well-being in persons with schizophrenia spectrum disorders.

Authors:  Lisa Hochstrasser; Stefan Borgwardt; Martin Lambert; Benno G Schimmelmann; Undine E Lang; Rolf-Dieter Stieglitz; Christian G Huber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-29       Impact factor: 5.270

2.  Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia.

Authors:  R S Wallwork; R Fortgang; R Hashimoto; D R Weinberger; D Dickinson
Journal:  Schizophr Res       Date:  2012-02-21       Impact factor: 4.939

3.  The impact of early family contact on quality of life among non-Hispanic Blacks and Whites in the RAISE-ETP trial.

Authors:  Oladunni Oluwoye; Liat Kriegel; Karl C Alcover; Michael T Compton; Leopoldo J Cabassa; Michael G McDonell
Journal:  Schizophr Res       Date:  2020-01-03       Impact factor: 4.939

4.  The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study.

Authors:  Alessandro Rossi; Silvana Galderisi; Paola Rocca; Alessandro Bertolino; Armida Mucci; Paola Rucci; Dino Gibertoni; Eugenio Aguglia; Mario Amore; Ileana Andriola; Antonello Bellomo; Massimo Biondi; Gaetano Callista; Anna Comparelli; Liliana Dell'Osso; Massimo Di Giannantonio; Andrea Fagiolini; Carlo Marchesi; Palmiero Monteleone; Cristiana Montemagni; Cinzia Niolu; Giuseppe Piegari; Federica Pinna; Rita Roncone; Paolo Stratta; Elena Tenconi; Antonio Vita; Patrizia Zeppegno; Mario Maj
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-07-06       Impact factor: 5.270

5.  Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia.

Authors:  Haya Ascher-Svanum; Diego Novick; Josep Maria Haro; Jaume Aguado; Zhanglin Cui
Journal:  Qual Life Res       Date:  2012-12-14       Impact factor: 4.147

Review 6.  Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options.

Authors:  Pierre Chue; Justine K Lalonde
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-08       Impact factor: 2.570

7.  Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study.

Authors:  Konstantinos N Fountoulakis; Elena Dragioti; Antonis T Theofilidis; Tobias Wikilund; Xenofon Atmatzidis; Ioannis Nimatoudis; Erik Thys; Martien Wampers; Luchezar Hranov; Trayana Hristova; Daniil Aptalidis; Roumen Milev; Felicia Iftene; Filip Spaniel; Pavel Knytl; Petra Furstova; Tiina From; Henry Karlsson; Maija Walta; Raimo K R Salokangas; Jean-Michel Azorin; Justine Bouniard; Julie Montant; Georg Juckel; Ida S Haussleiter; Athanasios Douzenis; Ioannis Michopoulos; Panagiotis Ferentinos; Nikolaos Smyrnis; Leonidas Mantonakis; Zsófia Nemes; Xenia Gonda; Dora Vajda; Anita Juhasz; Amresh Shrivastava; John Waddington; Maurizio Pompili; Anna Comparelli; Valentina Corigliano; Elmars Rancans; Alvydas Navickas; Jan Hilbig; Laurynas Bukelskis; Lidija Injac Stevovic; Sanja Vodopic; Oluyomi Esan; Oluremi Oladele; Christopher Osunbote; Janusz Κ Rybakowski; Pawel Wojciak; Klaudia Domowicz; Maria Luisa Figueira; Ludgero Linhares; Joana Crawford; Anca-Livia Panfil; Daria Smirnova; Olga Izmailova; Dusica Lecic-Tosevski; Henk Temmingh; Fleur Howells; Julio Bobes; Maria Paz Garcia-Portilla; Leticia García-Alvarez; Gamze Erzin; Hasan Karadağ; Avinash De Sousa; Anuja Bendre; Cyril Hoschl; Cristina Bredicean; Ion Papava; Olivera Vukovic; Bojana Pejuskovic; Vincent Russell; Loukas Athanasiadis; Anastasia Konsta; Dan Stein; Michael Berk; Olivia Dean; Rajiv Tandon; Siegfried Kasper; Marc De Hert
Journal:  Int J Neuropsychopharmacol       Date:  2019-11-01       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.